Amy Owen-Wyard: A Life Should Not Have a Price Tag Attached to Its Rarity
Amy Owen-Wyard, Director at EquiPath Analytics, Senior Mental Health Nurse at Herefordshire and Worcestershire Health and Care NHS Trust, shared a post on LinkedIn:
“Rare disease innovation is advancing, but only if your condition represents a viable market.
My son lives with Glanzmann Thrombasthenia, an ultra-rare bleeding disorder where platelets don’t function properly.
In the UK, the ‘gold standard’ treatment remains platelet transfusion.
However, repeated transfusions carry a significant risk: antibody development, rendering future transfusions ineffective.
We are now in that position.
The clinical solution offered? Continue using the same approach that increases the risk of complete refractoriness, despite there being no alternative pathway once immunity develops.
This is not a criticism of individual clinicians. It is a systemic failure of prioritisation.
Ultra-rare conditions remain under-researched because they are not commercially attractive.
Meanwhile, families manage significant clinical burden at home, bleeds, monitoring, crisis prevention, much of which is never captured in datasets because it never reaches hospital reporting systems.
If it isn’t recorded, it isn’t counted.
If it isn’t counted, it isn’t prioritised.
That is why we established a research company last year.
Our mission is simple:
- Ensure lived experience sits at the centre of research design and decision-making
- Capture real-world, home-managed data that is currently invisible
- Amplify the voices of families who are too often absent from regulatory and policy conversations
- Influence those with the power to change access, funding and innovation pathways
Equity in healthcare cannot depend on prevalence.
A life should not have a price tag attached to its rarity.
Rare Disease Day raises awareness, but awareness without structural change is not enough.
If you work in research, policy, commissioning, biotech, or regulation and believe patient voice should shape innovation. I would welcome a conversation.”

Stay updated with Hemostasis Today.
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same
-
Jul 19, 2026, 16:58Axel Cangas: Exploring the Future of Hemophilia Care at ISTH 2026
-
Jul 19, 2026, 16:58Aviva Schwartz: Air Pollution and Women’s Hematological Health in the Spotlight at ISTH 2026
-
Jul 19, 2026, 16:56Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
-
Jul 19, 2026, 16:54Belén de la Morena Barrio: Presenting Our Research on Long-Read Sequencing for Genetic Diagnosis at ISTH 2026
-
Jul 19, 2026, 16:52Shamee Shastry: Sometimes the Answer is Not in the Test Tube Alone, but at the Patient’s Bedside
-
Jul 19, 2026, 16:52Manuela Albisetti: Congratulations to Alessandra Bosch on an Outstanding ISTH 2026 Talk
-
Jul 19, 2026, 16:44Fernanda Orsi: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:37William Aird: A Visual Guide to Understanding von Willebrand Disease